Research programme: haemophilia therapy - 3B Pharmaceuticals/Shire

Drug Profile

Research programme: haemophilia therapy - 3B Pharmaceuticals/Shire

Latest Information Update: 15 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Baxalta; Jerini
  • Developer 3B Pharmaceuticals; Shire
  • Class Peptides
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Haemophilia

Most Recent Events

  • 03 Jun 2016 Baxalta has been acquired and merged into Shire
  • 13 Jan 2014 Preclinical trials in Haemophilia in Germany (unspecified route)
  • 31 Dec 2009 3B Pharmaceuticals acquires R&D assets of Jerini AG
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top